OrthoPediatrics Q3 revenue up 19% and tops estimates, guidance raised

what happened

US pediatric orthopedics device maker OrthoPediatrics reported third-quarter revenue up 19% year over year, reaching $72.7 million against analyst expectations of $68.5 million, according to Reuters. The company credited growth mainly to its trauma and deformity products and its OPSB line, along with higher procedure volumes and newly launched product lines.

Adjusted EBITDA for the quarter came in at $6.9 million, below the $8.38 million consensus. The company posted a net loss of $5.93 million and a gross margin of 74%. It raised full-year 2026 revenue guidance to $270 million–$273 million from $265 million–$269 million, and expects adjusted EBITDA of about $25 million and breakeven free cash flow.

why it matters

The guidance increase alongside revenue growth is the main positive signal, while the EBITDA miss and the net loss show that profitability is still under pressure. According to Reuters, analysts' average rating on the shares is buy, and the median 12-month price target is $25.00. The story concerns a small-cap company and is unlikely to move the broader market.

tags

instruments